Gui Zhi Yamada, general manager of Kanda Pharmaceutical (China) Co., Ltd. said that in other countries, the glaucoma market is generally the largest market. In China, glaucoma ranks fourth and fifth. This shows that there are many potential glaucoma patients who have not received treatment or drugs. This is also the case. Although there are a large number of glaucoma patients in China, the diagnosis and treatment situation is not optimistic. Statistics show that the diagnosis coverage of glaucoma in China is only about 10%. The low awareness of patients is one of the outstanding problems in the treatment of glaucoma at present. In addition, there are outstanding problems such as shortage of ophthalmologists and lack of ophthalmic products.
The goal of glaucoma treatment is to prevent further damage to visual function and improve the quality of life of patients. At present, the only treatment that can effectively control the progress of glaucoma is to reduce intraocular pressure. PG drugs have become the first-line drugs for open-angle glaucoma because of their outstanding intraocular pressure lowering effect, safety and patient compliance. Among them, Teplos Eye Drops introduced by Shentian Eye Drops is the first choice for patients with open angle glaucoma and high intraocular pressure. Its structure is unique and its affinity with FP receptor is 12 times that of latanoprost. Strong antihypertensive function, the intraocular pressure can be reduced by as much as 37.2%, and the patients with intraocular pressure decreased by more than 20% can be as high as 91.2%; Stable and lasting, controlling intraocular pressure fluctuation of glaucoma patients continuously and stably for 24 hours; High safety, conjunctival congestion is lower than other PG drugs.
Moreover, on 20 19128 October, 165438+ Tepple Eye Drops were officially included in the national medical insurance catalogue through national negotiations, which is the first-line drug for preventing glaucoma in the national medical insurance catalogue. There is no medical insurance payment limit, and the medical insurance payment price of Tepple Eye Drops has also dropped significantly to 74.8 yuan.
In addition, Shentian Eye Drops has actively carried out a series of activities to raise public awareness of glaucoma. In March, 2020, during the World Glaucoma Week, Kanda Eye Drops launched a series of activities in Japan, China, other Asian countries, Europe, the Middle East and Africa, the United States and other places with the theme of "patient-centered", aiming at enhancing public awareness and prevention of glaucoma and promoting people to find glaucoma as soon as possible.
In June, Shentian Eye Drops 2020 Glaucoma "Cloud" Summit was held in Shanghai. Well-known experts, scholars and mainstream media from the national ophthalmology field attended, shared the latest academic research results in the field of glaucoma, and conducted in-depth discussions on the optimization of glaucoma diagnosis and treatment strategies, the improvement of doctors' diagnosis and treatment technology in the field of glaucoma, and the public's cognition of glaucoma.
Shentian Eye Drops hopes to promote the public's understanding of glaucoma through cooperation with the media and academic experts, so that more glaucoma patients can see a doctor early and reduce the economic and living burden of blindness caused by glaucoma to society and families.
It is believed that in the future, Shentian Eye Drops will continue to develop and introduce more abundant and better eye drops, and strive to provide overall disease solutions for glaucoma patients, including from drug treatment to surgical instruments, from unilateral drugs to compound drugs, and from mild to moderate and severe glaucoma treatment.